|
1
|
Lamm D, Herr H, Jakse G, Kuroda M, Mostofi
FK, Okajima E, Sakamoto A, Sesterhenn I and da Silva FC: Updated
concepts and treatment of carcinoma in situ. Urol Oncol. 4:130–138.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Witjes JA, Palou J, Soloway M, Lamm D,
Kamat AM, Brausi M, Persad R, Buckley R, Colombel M and Böhle A:
Current clinical practice gaps in the treatment of intermediate-
and high-risk non-muscle-invasive bladder cancer (NMIBC) with
emphasis on the use of bacillus Calmette-Guérin (BCG): Results of
an international individual patient data survey (IPDS). BJU Int.
112:742–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shelley MD, Jones G, Cleves A, Wilt TJ,
Mason MD and Kynaston HG: Intravesical gemcitabine therapy for
non-muscle invasive bladder cancer (NMIBC): A systematic review.
BJU Int. 109:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A, Palou-Redorta J and Rouprêt M: European
Association of Urology (EAU): EAU guidelines on non-muscle-invasive
urothelial carcinoma of the bladder, the 2011 update. Eur Urol.
59:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pawinski A, Sylvester R, Kurth KH,
Bouffioux C, van der Meijden A, Parmar MK and Bijnens L: A combined
analysis of European organization for research and treatment of
cancer and medical research Council randomized clinical trials for
the prophylactic treatment of stage TaT1 bladder cancer. European
organization for research and treatment of cancer genitourinary
tract cancer cooperative group and the medical research council
working party on superficial bladder cancer. J Urol. 156:1934–1940;
discussion 1940–1941. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shelley MD, Kynaston H, Court J, Wilt TJ,
Coles B, Burgon K and Mason MD: A systematic review of intravesical
bacillus Calmette-Guérin plus transurethral resection vs.
transurethral resection alone in Ta and T1 bladder cancer. BJU Int.
88:209–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han RF and Pan JG: Can intravesical
bacillus Calmette-Guérin reduce recurrence in patients with
superficial bladder cancer? A meta-analysis of randomized trials.
Urology. 67:1216–1223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Böhle A, Jocham D and Bock PR:
Intravesical bacillus Calmette-Guerin versus mitomycin C for
superficial bladder cancer: A formal meta-analysis of comparative
studies on recurrence and toxicity. J Urol. 169:90–95. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sylvester RJ, van der Meijden AP and Lamm
DL: Intravesical bacillus Calmette-Guerin reduces the risk of
progression in patients with superficial bladder cancer: A
meta-analysis of the published results of randomized clinical
trials. J Urol. 168:1964–1970. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Böhle A and Bock PR: Intravesical bacille
Calmette-Guérin versus mitomycin C in superficial bladder cancer:
Formal meta-analysis of comparative studies on tumor progression.
Urology. 63:682–686; discussion 686–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malmström PU: Management of superficial
bladder cancer: What is new? Curr Opin Urol. 10:447–451. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shelley MD, Wilt TJ, Court J, Coles B,
Kynaston H and Mason MD: Intravesical bacillus Calmette-Guérin is
superior to mitomycin C in reducing tumour recurrence in high-risk
superficial bladder cancer: A meta-analysis of randomized trials.
BJU Int. 93:485–490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shelley MD, Mason MD and Kynaston H:
Intravesical therapy for superficial bladder cancer: A systematic
review of randomised trials and meta-analyses. Cancer Treat Rev.
36:195–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. Ann Intern Med.
151:W65–W94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Higgins JPT: Cochrane Collaboration
Handbook for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration. 2011.simplewww.cochrane-handbook.orgAccessed. November
12–2014
|
|
17
|
Sutton AJ, Duval SJ, Tweedie RL, Abrams KR
and Jones DR: Empirical assessment of effect of publication bias on
meta-analyses. BMJ. 320:1574–1577. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Friedrich MG, Pichlmeier U, Schwaibold H,
Conrad S and Huland H: Long-term intravesical adjuvant chemotherapy
further reduces recurrence rate compared with short-term
intravesical chemotherapy and short-term therapy with Bacillus
Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder
carcinoma. Eur Urol. 52:1123–1129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ojea A, Nogueira JL, Solsona E, Flores N,
Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez
RH, et al: A multicentre, randomised prospective trial comparing
three intravesical adjuvant therapies for intermediate-risk
superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27
mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus
mitomycin C. Eur Urol. 52:1398–1406. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Di Stasi SM, Giannantoni A, Stephen RL,
Capelli G, Navarra P, Massoud R and Vespasiani G: Intravesical
electromotive mitomycin C versus passive transport mitomycin C for
high risk superficial bladder cancer: A prospective randomized
study. J Urol. 170:777–782. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Malmström PU, Wijkström H, Lundholm C,
Wester K, Busch C and Norlén BJ: 5-year followup of a randomized
prospective study comparing mitomycin C and bacillus
Calmette-Guerin in patients with superficial bladder carcinoma.
Swedish-Norwegian bladder cancer study group. J Urol.
161:1124–1127. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krege S, Giani G, Meyer R, Otto T and
Rübben H: A randomized multicenter trial of adjuvant therapy in
superficial bladder cancer: Transurethral resection only versus
transurethral resection plus mitomycin C versus transurethral
resection plus bacillus Calmette-Guerin. Participating Clinics. J
Urol. 156:962–966. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rintala E, Jauhiainen K, Alfthan O,
Hansson E, Juusela H, Kanerva K, Korhonen H, Permi J, Sotarauta M,
Vaalasti T, et al: Intravesical chemotherapy (mitomycin C) versus
immunotherapy (bacillus Calmette-Guérin) in superficial bladder
cancer. Eur Urol. 20:19–25. 1991.PubMed/NCBI
|
|
24
|
Zhu S, Tang Y, Li K, Shang Z, Jiang N,
Nian X, Sun L and Niu Y: Optimal schedule of bacillus
calmette-guerin for non-muscle-invasive bladder cancer: A
meta-analysis of comparative studies. BMC Cancer. 13:3322013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malmström PU, Sylvester RJ, Crawford DE,
Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM and Witjes
JA: An individual patient data meta-analysis of the long-term
outcome of randomised studies comparing intravesical mitomycin C
versus bacillus Calmette-Guerin for non-muscle-invasive bladder
cancer. Eur Urol. 56:247–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoneyama T, Ohyama C, Imai A, Ishimura H,
Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T and
Suzuki T: Low-dose instillation therapy with bacille
Calmette-Guérin Tokyo 172 strain after transurethral resection:
Historical cohort study. Urology. 71:1161–1165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar A, Dubey D, Bansal P, Mandhani A and
Naik S: Urinary interleukin-8 predicts the response of standard and
low dose intravesical bacillus Calmette-Guerin (modified Danish
1331 strain) for superficial bladder cancer. J Urol. 168:2232–2235.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Irie A, Uchida T, Yamashita H, Matsumoto
K, Satoh T, Koh H, Shimura S, Iwamura M and Baba S: Sufficient
prophylactic efficacy with minor adverse effects by intravesical
instillation of low-dose bacillus Calmette-Guérin for superficial
bladder cancer recurrence. Int J Urol. 10:183–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
